A patient with a history of pancreatitis and cirrhosis is also being treated for hypertension. Which drug will most likely be ordered for this patient?

Choice A rationale Clonidine is a centrally acting alpha-2 adrenergic agonist. While it is an effective antihypertensive, it has been associated with adverse effects on the liver, including hepatitis and elevated liver enzymes. For a patient with a history of cirrhosis, which involves irreversible liver damage and impaired function, a drug with potential hepatotoxicity is a poor choice as it could worsen the underlying liver disease. Choice B rationale Prazosin is an alpha-1 adrenergic blocker. It is a suitable choice for this patient. Unlike other antihypertensives, it does not typically cause adverse effects on the liver or pancreas. Its mechanism of action, causing vasodilation by blocking alpha-1 receptors, is not known to exacerbate either pancreatitis or cirrhosis. Therefore, it is a safe and effective option given the patient's co-morbidities. Choice C rationale Diltiazem is a calcium channel blocker. While generally safe, some calcium channel blockers have been associated with potential exacerbation of pancreatic inflammation. Although diltiazem is not the most common culprit, its use should be approached with caution in a patient with a history of pancreatitis due to the potential for pancreatic adverse effects. This makes it a less ideal choice compared to a drug with no known pancreatic side effects. Choice D rationale Captopril is an ACE inhibitor. This class of drugs has been associated with a potential risk of hepatotoxicity, including cholestatic jaundice and liver failure, although these are rare. In a patient with pre-existing cirrhosis, the liver's ability to metabolize drugs is already compromised, which increases the risk of drug accumulation and potential toxicity. Therefore, it would be a less favorable choice due to the risk of worsening liver function.